Abstract
Purpose: The stability of 5-fluorouracil (FU) Roche solutions in a portable infusion pump under prolonged “in-use” conditions (32 °C, in the dark) was studied, especially with respect to the formation of the cardiotoxic compounds fluoroacetaldehyde (Facet) and fluoromalonic acid semialdehyde (FMASAld). Methods: The solutions, prepared according to three protocols frequently used at the Anticancer Centre in Toulouse, were analysed by 19F NMR immediately after preparation (T0) and after 2, 3 or 10 days (TF) in the pump. Results: The commercial solution already contained 64 fluorinated “impurities”, among them fluoride ion (F−), FMASAld and Facet. The concentration of FU did not change significantly between T0 and TF, whatever the protocol. The levels of F− had not increased significantly after 2 or 3 days, but had increased by about 50% after 10 days. The increases in FMASAld levels were low (12–28%) albeit significant in the three protocols. The levels of Facet had increased by a factor of about 2 after 2 or 3 days, and by a factor of >3 after 10 days. The levels of the other fluorinated compounds were constant during the first 2 or 3 days, but had increased by about 30% after 10 days. FU Dakota lyophilizates, analysed immediately after reconstitution, contained neither FMASAld nor Facet. After 2 days at 25 °C, low levels of FMASAld were present but Facet could still not be detected. Conclusion: This study showed that special attention must be paid to the risk of increasing concentrations of highly toxic FMASAld and Facet when FU is administered via a pump for long periods of time. It would be preferable not to exceed 3 days of treatment when patients receive FU from a portable infusion pump. This underlines the interest in using a lyophilized formulation of FU in clinical practice.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 25 October 1999 / Accepted: 25 July 2000
Rights and permissions
About this article
Cite this article
Fournet, A., Gilard, V., Malet-Martino, M. et al. Stability of commercial solutions of 5-fluorouracil for continuous infusion in an ambulatory pump. Cancer Chemother Pharmacol 46, 501–506 (2000). https://doi.org/10.1007/s002800000182
Issue Date:
DOI: https://doi.org/10.1007/s002800000182